Ovarian cancer

[edit] Americola's celebrity biographies are provided by AmericolaWiki, a celebrity wiki. You can help contribute to Americola and edit this article.

Ovarian cancer
Classification & external resources

ICD-10	C56.
ICD-9	183
ICD-O:	varied
DiseasesDB	9418
MedlinePlus	000889
eMedicine	med/1698

Ovarian cancer is a malignant ovarian neoplasm (an abnormal growth located on the ovaries).

Contents 1 Causes 2 Classification 2.1 Histology 2.2 History 3 Staging 4 Treatment 5 Symptoms 6 Diagnosis 7 Expectations (prognosis) 8 Complications 9 Notable women with ovarian cancer 10 See also 11 References 12 External links

Causes

Ovarian cancer is the fifth leading cause of cancer death in women, the leading cause of death from gynecological malignancy, and the second most commonly diagnosed gynecologic malignancy ^[1].

It is idiopathic, meaning that the exact cause is usually unknown. The disease is more common in industrialized nations, with the exception of Japan. In the United States, females have a 1.4% to 2.5% (1 out of 40-60 women) lifetime chance of developing ovarian cancer.

Older women are at highest risk. More than half of the deaths from ovarian cancer occur in women between 55 and 74 years of age and approximately one quarter of ovarian cancer deaths occur in women between 35 and 54 years of age.

The risk for developing ovarian cancer appears to be affected by several factors. The more children a woman has, the lower her risk of ovarian cancer. Early age at first pregnancy, older ages of final pregnancy and the use of low dose hormonal contraception have also been shown to have a protective effect. Ovarian cancer is reduced in women after tubal ligation.

The link to the use of fertility medication, such as Clomiphene citrate, has been controversial. An analysis in 1991 raised the possibility that use of drugs may increase the risk for ovarian cancer. Several cohort studies and case-control studies have been conducted since then without providing conclusive evidence for such a link. ^[2] It will remain a complex topic to study as the infertile population differs in parity from the "normal" population.

There is good evidence that in some women genetic factors are important. Carriers of certain mutations of the BRCA1 or the BRCA2 gene, more frequent in some populations (e.g. Ashkenazi Jewish women) are at a higher risk of both breast cancer and ovarian cancer, often at an earlier age than the general population. Patients with a personal history of breast cancer or a family history of breast and/or ovarian cancer, especially if at a young age, may have an elevated risk. A strong family history of uterine cancer, colon cancer, or other gastrointestinal cancers may indicate the presence of a syndrome known as hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch II syndrome), which confers a higher risk for developing ovarian cancer. Patients with strong genetic risk for ovarian cancer may consider the use of prophylactic oophorectomy after completion of child-bearing.

A Swedish study, which followed more than 61,000 women for 13 years, has found a significant link between milk consumption and ovarian cancer. According to the BBC, "[Researchers] found that milk had the strongest link with ovarian cancer - those women who drank two or more glasses a day were at double the risk of those who did not consume it at all, or only in small amounts." ^[3] Recent studies have shown that women in sunnier countries have a lower rate of ovarian cancer, which may have some kind of connection with exposure to Vitamin D.^{[citation needed]}

Other factors that have been investigated, such as talc use, asbestos exposure, high dietary fat content, and childhood mumps infection, are controversial and have not been definitively proven.

"Associations were also found between alcohol consumption and cancers of the ovary and prostate, but only for 50 g and 100 g a day."^[4]

Classification

Histology

Ovarian cancer is classified according to the histology of the tumor. Lesions differ significantly in clinical features, management, and prognosis (ICD-O codes provided where available):

• Surface epithelial-stromal tumours are the most common and prototypic ovarian cancers. They are thought to originate from the ovarian surface lining, and include serous cystadenocarcinoma (8441/3), and mucinous cystadenocarcinoma (8470/3). The abdominal cavity is lined with the same cells that make up the ovarian surface lining, and it is possible to have cancer begin there, in which case, it is called primary peritoneal cancer. Treatment, however, is basically the same as treatment for ovarian cancer.
• Sex cord-stromal tumors include lesions that are hormonally active such as the estrogen-producing granulosa cell tumor (8620/3) and the virilizing Sertoli-Leydig cell tumor or arrhenoblastoma.
• Germ cell tumors originate from dysplastic germ material and tend to occur in young women and girls. Lesions include the dysgerminoma (9060/3), a form of the choriocarcinoma (9100/3), and malignant forms of the teratoma (9083/3). Malignant teratoma often contains endodermal sinus tumor (9071/3).

History

Ovarian cancer often is primary, but can also be secondary, the result of metastasis from primary cancers elsewhere in the body. For example, from breast cancer, or from gastrointestinal cancer (in which case the ovarian cancer is a Krukenberg cancer).

Staging

Ovarian cancer staging is by the FIGO staging system and uses information obtained after surgery, which can include a total abdominal hysterectomy, removal of (usually) both ovaries and fallopian tubes, (usually) the omentum, and pelvic (peritoneal) washings for cytology. The AJCC stage is the same as the FIGO stage.

• Stage I - limited to one or both ovaries
  • IA - involves one ovary; capsule intact; no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings
  • IB - involves both ovaries; capsule intact; no tumor on ovarian surface; negative washings
  • IC - tumor limited to ovaries with any of the following: capsule ruptured, tumor on ovarian surface, positive washings
• Stage II - pelvic extension or implants
  • IIA - extension or implants onto uterus or fallopian tube; negative washings
  • IIB - extension or implants onto other pelvic structures; negative washings
  • IIC - pelvic extension or implants with positive peritoneal washings
• Stage III - microscopic peritoneal implants outside of the pelvis; or limited to the pelvis with extension to the small bowel or omentum
  • IIIA - microscopic peritoneal metastases beyond pelvis
  • IIIB - macroscopic peritoneal metastases beyond pelvis less than 2 cm in size
  • IIIC - peritoneal metastases beyond pelvis > 2 cm or lymph node metastases
• Stage IV - distant metastases--in the liver, or outside the peritoneal cavity

Para-aortic lymph node metastases are considered regional lymph nodes (Stage IIIC).

Treatment

Surgery is the preferred treatment and is frequently necessary for diagnosis. Studies have shown that surgery performed by a specialist in gynecologic oncology usually result in an improved outlook. Improved survival is attributed to more accurate staging of the disease and a higher rate of aggressive surgical excision of tumor in the abdomen by gynecologic oncologists as opposed to general gynecologists and general surgeons.

The type of surgery depends upon how widespread the cancer is when diagnosed (the cancer stage), as well as the type and grade of cancer. The surgeon may remove one (unilateral oophorectomy) or both ovaries (bilateral oophorectomy), the fallopian tubes (salpingectomy), and the uterus (hysterectomy). For some very early tumors (stage 1, low grade or low-risk disease), only the involved ovary and fallopian tube will be removed (called a "unilateral salpingo-oophorectomy," USO), especially in young females who wish to preserve their fertility. In advanced disease as much tumor as possible is removed (debulking surgery). In cases where this type of surgery is successful, the prognosis is improved compared to patients where large tumour masses (more than 1 cm in diameter) are left behind.

Chemotherapy is used as after surgery to treat any residual disease. At present many oncologists are still recommending systemic chemotherapy including a platinum derivative with a taxane as a preferred method of treating advanced ovarian cancer. However, randomized, multicenter clinical trials are beginning to clearly show that Intra-peritoneal chemotherapy produces longer survival times. As this therapy may not always be available in local hospitals, women should consult doctors based in nationally recognized centers as soon after diagnosis as possible in order to select the most effective treatment plan. Chemotherapy can also be used to treat women who have a recurrence.

Three large randomized studies of the Gynecologic Oncology Group have suggested that chemotherapy regimens delivered partly via direct infusion into the abdominal cavity (intraperitoneal or "IP") improve median survival time over regimens that are only given intravenously (in the vein or "IV"). Reported toxicities are generally higher and the advantages of IP chemotherapy are still debated among specialists.

Radiation therapy is not effective for advanced stages because when vital organs are in the radiation field, a high dose cannot be safely delivered.

Pre-clinical chemosensitivity and chemoresistance testing is being done by laboratories in the USA, Europe, and Asia.

Symptoms

• sense of pelvic heaviness
• vaginal bleeding
• weight gain or weight loss
• abnormal menstrual cycles
• unexplained back pain that worsens over time
• increased abdominal girth
• non specific gastrointestinal symptoms:
  • vague lower abdominal discomfort
  • increased gas
  • indigestion
  • lack of appetite
  • nausea and vomiting
  • Bloody stool
  • inability to ingest usual volumes of food
  • bloating
• Additional symptoms that may be associated with this disease:
  • increased urinary frequency/urgency
  • excessive hair growth
  • Fluid buildup in the lining around the lungs (Pleural effusions)
  • Positive pregnancy readings (in the absence of pregnancy. This is for germ cell tumors only)

Note: There may be no symptoms until late in the disease.

Diagnosis

Ovarian cancer at its early stages(I/II) is difficult to diagnose until it spreads and advances to later stages(III/IV). This is due to the fact that most of the common symptoms are non-specific.

The blood test called CA-125 is useful in differential diagnosis and in follow up of the disease, but it has not been shown to be an effective method to screen for early-stage ovarian cancer and is currently not recommended for this use.

A study funded by the American Cancer Society conducted at the H. Lee Moffitt Cancer Center & Research Institute has found a correlation between high levels of lysophospholipids (a type of fatty acid) with ovarian cancer patients and low levels of lysophospholipids with healthy women. This potential biomarker can be detected by a simple blood test. The blood test was 93% accurate as predictor of ovarian cancer with less than 4% false positives of the 117 women studied.^[5]

Current research is looking at ways to combine tumor markers along with other indicators of disease (i.e. radiology and/or symptoms) to improve accuracy. The challenge in such an approach is that the very low population prevelance of ovarian cancer means that even testing with very high sensitivity and specificity will still lead to unacceptable numbers of false positive results. This is exemplified by the recent discovery of proteomic predictors that showed 100% sensitivity and 95% specificity. ^[6]

A pelvic examination, including CT scan, trans-vaginal ultrasound, is also of utility. Physical examination may reveal increased abdominal girth and /or ascites (fluid within the abdominal cavity). Pelvic examination may reveal an ovarian or abdominal mass. The pelvic exam can include a rectovaginal component for better palpation of the ovaries.

Expectations (prognosis)

Ovarian cancer has a poor prognosis. It is disproportionately deadly because symptoms are vague and non-specific. More than 60% of patients presenting with this disease already have stage III or stage IV disease, when it has already spread beyond the ovaries.

Ovarian cancers shed malignant cells into the naturally occurring fluid within the abdominal cavity. These cells then have the potential to float in this fluid and frequently implant on other abdominal (peritoneal) structures included the uterus, urinary bladder, bowel, and lining of the bowel wall (omentum). These cells can begin forming new tumor growths before cancer is even suspected.

More than 50% of women with ovarian cancer are diagnosed in the advanced stages of the disease because no cost-effective screening test for ovarian cancer exists. The five year survival rate for all stages is only 35% to 38%. If, however, diagnosis is made early in the disease, five-year survival rates can reach 90% to 98%.

Germ Cell Ovarian Cancer has a much better prognosis, but is rarer.

Complications

• spread of the cancer to other organs
• progressive function loss of various organs
• ascites (fluid in the abdomen)
• blockage of the intestines

Notable women with ovarian cancer

• Evelyn Ankers, actress (died at age 67; see [1])
• Eileen Barton, Brooklyn-born American singer ( died at age 81)
• Raelene Boyle, Australian athlete; surviving
• Laurie Beechman, actress/singer (died at age 43)
• Marcheline Bertrand, actress and mother of Angelina Jolie (died age 56)
• Clare Boylan, Irish writer (died at age 58)
• Jill Chaifetz, American lawyer and children's right advocate (died at age 41)
• Carol Channing, actress/entertainer; surviving
• Caitlin Clarke, actress (died at age 52)
• Sister Sarah Clarke, County Galway, Ireland-born Roman Catholic nun and London-based political activist during The Troubles (1980s-1990s); survived; died of natural causes.
• Elizabeth Connors, teacher/women's rights activist (died at age 43)
• Helen Cresswell, British writer and author (died at age 71)
• U.S. Congresswoman Rosa DeLauro, surviving (see [2])
• Mildred Dean, mother of American actor James Dean; she died when Dean was 9 years old (see [3]).
• Sandy Dennis, Oscar-winning actress (died at age 54)
• Diana Dors, actress, also known as Diana d'Ors (died at age 52)
• Patricia C. Dunn, embattled former chair of Hewlett-Packard, currently battling ovarian cancer.
• Robert Eads, American female to male transsexual who was denied medical treatment for the cancer in the state of Georgia (died at age 53)
• Jeannie Ferris, Senator for South Australia (died at age 66)
• Susan Fleetwood, British actress (died at age 51)
• Rosalind Franklin, British physical chemist and crystallographer, linked with the discovery of the shape of the double helix of DNA (died at age 37)
• Lynda Gibson, Australian comedian and actress (died at age 47)
• Ella Grasso, former Connecticut governor, and the first woman ever to be elected governor in her own right (died at age 61)
• Cassandra Harris, Australian actress/wife of Pierce Brosnan (died at age 43)
• Dolly Haas, actress/singer; wife of Al Hirschfeld (died at age 84)
• Joan Hackett, actress (died at age 49)
• Joyce Hatto, English pianist (died at age 77)
• Madeline Kahn, actress, singer and comedienne (died at age 57)
• Coretta Scott King, civil rights activist; widow of the Rev. Martin Luther King, Jr. (died at age 78)
• Joyce Kulhawik, film critic and Boston television personality; former TV co-host of movie critic Leonard Maltin; surviving.
• Sarabeth Kusick, wife of baseball player Craig Kusick (who died from leukemia nine months following his wife's death)
• Dixie Lee, actress/singer; converted to marry Bing Crosby (died at age 40)
• Janet Margolin, actress (died at age 50)
• Mary I of England, née Mary Tudor; British Queen Mary I (died either of uterine cancer or ovarian cancer at the age of 42)
• Heather Menzies, Canadian actress, most famous for portraying Louisa in The Sound of Music and widow of Robert Urich; surviving
• Mary Millar, British actress, most famous as "Rose" from Keeping Up Appearances (died at age 62)
• Helen Simpson Morosini, mother of the late singer/actress/activist Dana Reeve (died at age 71)
• Bess Myerson, former Miss America, surviving
• Laura Nyro, singer (died at age 49; her own mother, Gilda Nigro, also died of ovarian cancer and at the same age as Nyro)
• Alice Pearce, actress (died at age 48)
• Gilda Radner, actress/comedienne/Saturday Night Live alumna (died at age 42)
• Patsy Ramsey, mother of the late JonBenét Ramsey (died at age 49)
• Janet Sandell, South African social activist (died at age 70)
• Dinah Shore, actress/singer (died at age 77)
• Linda Smith, comedienne, actress; head of the British Humanists' Association (died at age 48)
• Jessica Tandy, actress (died at age 85)
• Liz Tilberis, Harper's Bazaar Editor-in-Chief (died at age 51)
• Joyce Wadler, New York journalist and New York Times columnist; surviving
• Angela Winbush, American rhythm and blues vocalist; surviving
• Loretta Young, Oscar-winning actress (died at age 87)

See also

• Germ cell ovarian cancer
• Desmoplastic small round cell tumor

References

1. ^ The Merck Manual of Diagnosis and Therapy Section 18. Gynecology And Obstetrics Chapter 241. Gynecologic Neoplasms
2. ^ Brinton LA et al Ovulation induction and cancer risk. Fertil Steril 2005;83:261-74.
3. ^ BBC News Milk link to ovarian cancer risk 29 November 2004
4. ^ Alcohol consumption and cancer risk
5. ^ Journal of Cancer Epidemiology, Biomarkers & Prevention July 7, 2004
6. ^ Petricoin, E. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (February 16, 2002).)

Wikipedia information about Ovarian cancer This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ovarian cancer". It may not have been reviewed by professional editors (see full disclaimer). Help contribute to Americola and edit this article.